![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: UGCG |
Gene summary for UGCG |
![]() |
Gene information | Species | Human | Gene symbol | UGCG | Gene ID | 7357 |
Gene name | UDP-glucose ceramide glucosyltransferase | |
Gene Alias | GCS | |
Cytomap | 9q31.3 | |
Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | A0A024R157 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7357 | UGCG | CA_HPV_1 | Human | Cervix | CC | 7.00e-11 | 4.94e-01 | 0.0264 |
7357 | UGCG | CCI_1 | Human | Cervix | CC | 2.03e-02 | 8.91e-01 | 0.528 |
7357 | UGCG | CCI_2 | Human | Cervix | CC | 3.32e-08 | 1.08e+00 | 0.5249 |
7357 | UGCG | CCI_3 | Human | Cervix | CC | 9.96e-09 | 8.33e-01 | 0.516 |
7357 | UGCG | sample3 | Human | Cervix | CC | 6.56e-06 | 3.00e-01 | 0.1387 |
7357 | UGCG | T3 | Human | Cervix | CC | 1.43e-03 | 2.94e-01 | 0.1389 |
7357 | UGCG | AEH-subject4 | Human | Endometrium | AEH | 1.80e-13 | 6.21e-01 | -0.2657 |
7357 | UGCG | EEC-subject1 | Human | Endometrium | EEC | 7.96e-05 | 4.21e-01 | -0.2682 |
7357 | UGCG | EEC-subject3 | Human | Endometrium | EEC | 1.78e-09 | 2.33e-01 | -0.2525 |
7357 | UGCG | GSM5276934 | Human | Endometrium | EEC | 1.83e-05 | 3.73e-01 | -0.0913 |
7357 | UGCG | GSM5276937 | Human | Endometrium | EEC | 1.62e-11 | 5.17e-01 | -0.0897 |
7357 | UGCG | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 4.22e-08 | -3.96e-02 | -0.1869 |
7357 | UGCG | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 9.89e-06 | -5.58e-02 | -0.1875 |
7357 | UGCG | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 9.24e-08 | -1.74e-01 | -0.1883 |
7357 | UGCG | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 8.71e-07 | 6.23e-02 | -0.1934 |
7357 | UGCG | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 2.93e-15 | -1.55e-01 | -0.1917 |
7357 | UGCG | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 5.79e-11 | -1.70e-01 | -0.1916 |
7357 | UGCG | LZE4T | Human | Esophagus | ESCC | 3.30e-04 | 1.07e-01 | 0.0811 |
7357 | UGCG | LZE7T | Human | Esophagus | ESCC | 1.03e-02 | 1.45e-01 | 0.0667 |
7357 | UGCG | LZE8T | Human | Esophagus | ESCC | 7.09e-04 | 2.95e-01 | 0.067 |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00988562 | Stomach | CAG | intestinal lipid absorption | 4/552 | 21/18723 | 3.00e-03 | 3.00e-02 | 4 |
GO:0019221 | Stomach | CAG | cytokine-mediated signaling pathway | 25/552 | 472/18723 | 3.63e-03 | 3.38e-02 | 25 |
GO:0061436 | Stomach | CAG | establishment of skin barrier | 4/552 | 25/18723 | 5.78e-03 | 4.73e-02 | 4 |
GO:00075865 | Stomach | SIM | digestion | 24/708 | 137/18723 | 3.20e-10 | 6.29e-08 | 24 |
GO:00226005 | Stomach | SIM | digestive system process | 18/708 | 104/18723 | 6.37e-08 | 6.30e-06 | 18 |
GO:00508924 | Stomach | SIM | intestinal absorption | 11/708 | 41/18723 | 2.34e-07 | 1.68e-05 | 11 |
GO:00988564 | Stomach | SIM | intestinal lipid absorption | 7/708 | 21/18723 | 7.85e-06 | 2.99e-04 | 7 |
GO:00192212 | Stomach | SIM | cytokine-mediated signaling pathway | 32/708 | 472/18723 | 1.10e-03 | 1.43e-02 | 32 |
GO:00108764 | Stomach | SIM | lipid localization | 30/708 | 448/18723 | 1.87e-03 | 2.08e-02 | 30 |
GO:00614361 | Stomach | SIM | establishment of skin barrier | 5/708 | 25/18723 | 2.16e-03 | 2.26e-02 | 5 |
GO:00068693 | Stomach | SIM | lipid transport | 27/708 | 398/18723 | 2.58e-03 | 2.55e-02 | 27 |
GO:005087841 | Stomach | SIM | regulation of body fluid levels | 26/708 | 379/18723 | 2.64e-03 | 2.58e-02 | 26 |
GO:0033561 | Stomach | SIM | regulation of water loss via skin | 5/708 | 27/18723 | 3.08e-03 | 2.94e-02 | 5 |
GO:004409110 | Thyroid | PTC | membrane biogenesis | 34/5968 | 55/18723 | 4.64e-06 | 5.69e-05 | 34 |
GO:007170914 | Thyroid | PTC | membrane assembly | 31/5968 | 50/18723 | 1.12e-05 | 1.23e-04 | 31 |
GO:004409114 | Thyroid | ATC | membrane biogenesis | 34/6293 | 55/18723 | 1.69e-05 | 1.56e-04 | 34 |
GO:007170915 | Thyroid | ATC | membrane assembly | 31/6293 | 50/18723 | 3.66e-05 | 2.99e-04 | 31 |
GO:0050878112 | Thyroid | ATC | regulation of body fluid levels | 149/6293 | 379/18723 | 1.08e-02 | 3.90e-02 | 149 |
Page: 1 2 3 4 5 6 7 8 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa006003 | Esophagus | ESCC | Sphingolipid metabolism | 36/4205 | 53/8465 | 5.41e-03 | 1.36e-02 | 6.99e-03 | 36 |
hsa0060012 | Esophagus | ESCC | Sphingolipid metabolism | 36/4205 | 53/8465 | 5.41e-03 | 1.36e-02 | 6.99e-03 | 36 |
hsa00600 | Liver | HCC | Sphingolipid metabolism | 34/4020 | 53/8465 | 1.06e-02 | 2.71e-02 | 1.51e-02 | 34 |
hsa006001 | Liver | HCC | Sphingolipid metabolism | 34/4020 | 53/8465 | 1.06e-02 | 2.71e-02 | 1.51e-02 | 34 |
hsa006002 | Oral cavity | OSCC | Sphingolipid metabolism | 33/3704 | 53/8465 | 5.00e-03 | 1.20e-02 | 6.13e-03 | 33 |
hsa0060011 | Oral cavity | OSCC | Sphingolipid metabolism | 33/3704 | 53/8465 | 5.00e-03 | 1.20e-02 | 6.13e-03 | 33 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
UGCG | SNV | Missense_Mutation | c.706N>C | p.Asp236His | p.D236H | Q16739 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
UGCG | SNV | Missense_Mutation | novel | c.769N>C | p.Ala257Pro | p.A257P | Q16739 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
UGCG | SNV | Missense_Mutation | c.187N>T | p.Asp63Tyr | p.D63Y | Q16739 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-IR-A3LI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
UGCG | SNV | Missense_Mutation | novel | c.272N>C | p.Asp91Ala | p.D91A | Q16739 | protein_coding | tolerated(0.29) | benign(0.218) | TCGA-ZJ-AAX8-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
UGCG | SNV | Missense_Mutation | novel | c.226N>A | p.Leu76Met | p.L76M | Q16739 | protein_coding | tolerated(0.71) | benign(0.209) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
UGCG | SNV | Missense_Mutation | novel | c.268C>A | p.His90Asn | p.H90N | Q16739 | protein_coding | tolerated(0.24) | benign(0) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
UGCG | SNV | Missense_Mutation | c.767T>C | p.Val256Ala | p.V256A | Q16739 | protein_coding | tolerated(0.4) | possibly_damaging(0.447) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD | |
UGCG | SNV | Missense_Mutation | novel | c.79T>G | p.Phe27Val | p.F27V | Q16739 | protein_coding | tolerated(0.31) | benign(0) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
UGCG | SNV | Missense_Mutation | c.800N>A | p.Ser267Tyr | p.S267Y | Q16739 | protein_coding | tolerated(0.05) | benign(0.011) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
UGCG | SNV | Missense_Mutation | novel | c.109N>A | p.Leu37Ile | p.L37I | Q16739 | protein_coding | deleterious(0.01) | possibly_damaging(0.854) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7357 | UGCG | ENZYME, DRUGGABLE GENOME | Eliglustat tartrate | |||
7357 | UGCG | ENZYME, DRUGGABLE GENOME | inhibitor | CHEMBL2103853 | ||
7357 | UGCG | ENZYME, DRUGGABLE GENOME | inhibitor | CHEMBL1029 | MIGLUSTAT | |
7357 | UGCG | ENZYME, DRUGGABLE GENOME | MIGLUSTAT | MIGLUSTAT | ||
7357 | UGCG | ENZYME, DRUGGABLE GENOME | ADRIAMYCIN | ADRIAMYCIN | 10702281 | |
7357 | UGCG | ENZYME, DRUGGABLE GENOME | ELIGLUSTAT | ELIGLUSTAT | ||
7357 | UGCG | ENZYME, DRUGGABLE GENOME | Miglustat | MIGLUSTAT | ||
7357 | UGCG | ENZYME, DRUGGABLE GENOME | GZ402671 | VENGLUSTAT | ||
7357 | UGCG | ENZYME, DRUGGABLE GENOME | Venglustat | VENGLUSTAT | ||
7357 | UGCG | ENZYME, DRUGGABLE GENOME | Genz-682452 | VENGLUSTAT |
Page: 1 2 |